Search

Endothelin receptors have been identified on astrocytes and astrocytoma, but their physiological significance has remained elusive. It is shown here that endothelins induce c-fos in primary cultures of mouse embryo astrocytes, as well as in two subclones of rat astrocytoma C6 cells, although with different kinetics. In addition, nerve growth factor expression is stimulated, as seen by mRNA accumulation and protein secretion, in primary astrocytes and one of the two C6 subclones, with an apparent correlation with the transience of c-fos induction. The activation of protein kinase C appears as an obligatory step during these processes, because (a) inhibition of protein kinase C by staurosporine blocks the induction by endothelin or phorbol esters of both c-fos and nerve growth factor, and (b) phorbol ester-evoked down-regulation of protein kinase C completely abolishes the c-fos induction by endothelin, but not that by the beta-adrenergic agonist isoproterenol, a known activator of the cyclic AMP-dependent pathway. Our results support the hypothesis that c-fos product might be implicated in nerve growth factor expression by astrocytes, and also suggest that endothelins may participate in vivo in the modulation of the glial neurotrophic activity during brain development or wound healing.

Inbred strains of mice, which produce high levels of submaxillary gland (SMG) renin have two renin genes, Ren 1 and Ren 2, per haploid genome, while strains with low levels of SMG renin have only the Ren 1 gene. Ren 1 codes for a glycosylated protein and Ren 2 codes for a highly homologous but unglycosylated and less thermostable protein. In order to determine if this difference in thermostability is related to the absence of glycosylation of renin-2 and/or to some amino acid difference between both renins we have compared the thermostability of renin-2 and a renin-2 mutant containing two potential N-glycosylation sites added by in vitro mutagenesis. Both mutant and wild type renins were expressed in AtT20 cells. Wild type renin was significantly less stable than the glycosylated mutant form upon heating. Moreover, the kinetics of heat inactivation of the mutant, in vitro deglycosylated form was similar to that of the wild type renin. This result indicates that glycosylation affects the thermostability of renin.

Most mouse inbred strains carry two renin genes, Ren-1 and Ren-2, Renin-2, the product of the Ren-2 gene, is highly expressed in the submaxillary gland. It is a renin isoenzyme 96% similar to kidney renin-1, but unglycosylated. In order to investigate if glycosylation of prorenin affects its processing and/or secretion we have introduced two potential N-linked glycosylation sites into preprorenin-2 cDNA using site-directed mutagenesis. Expression plasmids were derived from wild-type and mutant renin-2 cDNA and were transfected into AtT20 cells. Both transfected cells, expressing glycosylated or unglycosylated forms, secreted prorenin and renin by the constitutive and regulated pathways, respectively. Prorenin was correctly processed to active renin but the second maturation site was not cleaved in AtT20 cells. The comparison of glycosylated and unglycosylated renin expression showed a diminished secretion of glycosylated active renin. Prevention of glycosylation with tunicamycin resulted in an improved secretion of active renin. Moreover, the efficiency of the trypsin activation in vitro was reduced for glycosylated prorenin and it was restored when the activation was performed on mutant renin secreted from tunicamycin-treated cells. It is proposed that the bulky carbohydrates attached to prorenin constitute a steric hindrance to proteolysis by maturation enzymes.

The role of prolactin on some ovarian functions was studied in collagenase-dispersed luteal cells obtained from PMSG/hCG-primed rats. The in vitro effect of ovine prolactin (oPrl) on luteal cell function was assayed. This hormone produced a dose-dependent increase of progesterone production and an additive effect on hCG stimulation. oPrl had no effect on cAMP production. Chronic effects of prolactin were studied in sulpiride (S), bromocriptine (Br) and oPrl-treated rats. Serum levels of prolactin were significantly higher in S-treated animals whereas Br administration rendered undetectable values. Serum progesterone was reduced in Br-treated animals and LH levels were similar in all groups studied. In vitro studies demonstrated a marked reduction of hCG stimulation of progesterone and cAMP production by luteal cells from hypoprolactinemic animals, while a significant increase was observed in hyperprolactinemic states. oPrl and S treatment significantly increased ovarian LH binding sites while a reduction was observed in Br-treated rats. These data suggest that luteal cell function is regulated by circulating levels of prolactin and that this hormone has some direct effect on the steroidogenic process.

The role of prolactin (Prl) in the regulation of Prl binding to its specific binding sites was studied in the Langerhans islets, adrenal gland and liver of adult ovariectomized female rats. Animals were sc injected twice daily during 10 days with ovine Prl (1 mg/kg BW), sulpiride (30 mg/kg BW) and bromocriptine (3 mg/kg BW). At the end of the treatment period, the animals were killed and serum was collected for Prl assay. Total Prl binding sites were measured in the membrane fraction of tissue by desaturating the occupied membrane receptors in vitro with 4M MgCl2. Serum levels of Prl were significantly higher in sulpiride-treated animals, whereas bromocriptine administration rendered undetectable values. Prolactin and sulpiride treatment significantly reduced Prl binding to the adrenal gland and Langerhans islets, whereas it greatly increased Prl binding to the liver. On the other hand, bromocriptine increased Prl binding sites in the adrenal gland and Langerhans islets, but in the liver caused no apparent effect. The binding affinity (Ka) in each tissue remained unchanged under the different experimental conditions. In addition, the binding of Prl to pancreas islets membranes was lower in late pregnancy when compared with control rats. All of these data provide strong evidence in favor of a role for Prl in regulating the number of its own tissue binding sites.

The present study examined the effects of streptozotocin-induced diabetes on prolactin (Prl) secretion and its correlation with estrogen receptor levels in the anterior pituitary and hypothalamus. Prl was measured in adult ovariectomized rats and after estradiol treatment (10 micrograms estradiol benzoate (Eb) 48, 24 and 1 h before experiments) or acute TRH administration (4 micrograms/kg body weight). Substantial decreases in estradiol- and TRH-induced Prl release were observed in diabetic rats. Insulin therapy was able to restore this response. Measurement of nuclear estradiol receptors by exchange assay in the pituitary of Eb-treated rats revealed a significant reduction in receptor levels in the diabetic group and a restoration to normal values in insulin-treated diabetic rats. Similar results were obtained by measuring total pituitary receptor content (cytosolic plus nuclear receptors). No significant changes were observed in nuclear hypothalamic estradiol receptors. However, the number of total hypothalamic estradiol receptors was diminished in diabetic rats although the translocation was proportionally greater in these animals. These results indicate that the disrupted reproductive functions described in streptozotocin diabetic rats may be due, at least in part, to deficiencies in Prl secretion and pituitary estradiol action.

The effect of insulin on cyclic nucleotide phosphodiesterase (PDE) in rat luteal cells was studied. Cells were obtained from PMSG/hCG primed rats and further incubated or not with insulin. The hormone produced an increase of enzyme activity after a 10 min incubation of intact cells. Maximal stimulation was achieved at 0.2 nM of insulin. Two peaks of cyclic nucleotide phosphodiesterase activity were resolved after chromatography of cell cytosolic extracts on DEAE-cellulose. These peaks (I and II) were active with cAMP as substrate but only peak I was active with cGMP. The enzyme activity of both peaks was increased in cells treated with insulin. Phosphodiesterase activity in the two peaks show two kinetic components for cAMP hydrolysis, one of high affinity (Km 2-4 microM) and the other of low affinity (47-56 microM). Treatment of the cells with insulin produced a 2 to 8 fold increase of the Vmax of these peaks. In addition after stimulation with insulin, the activation of peak I phosphodiesterase by calmodulin was less effective.

The effect of streptozotocin diabetes on some ovarian functions in adult rats was examined. Diabetic diestrus animals showed reduced ovary weight and lower circulating levels of progesterone. Scatchard plots of binding data derived from ovarian particulate fractions of normal and streptozotocin diabetic rats revealed the presence of one class of binding sites with high affinity for 125I-hCG. The apparent association constant of the hCG receptors of diabetic ovaries was comparable to that of normal gonads. However, a marked decrease (42%) in the number of hCG binding sites was found in diabetic animals. With isolated luteal cells similar results were obtained, and the administration of insulin to streptozotocin diabetic rats restored to normality the number of hCG binding sites. The maximal response of progesterone production by luteal cells from control ovaries was obtained with 10(-10) M hCG. A 100-fold higher concentration of hCG was required for the maximum stimulation of cAMP synthesis. The cAMP response of cells from diabetic rats was significantly higher than that of control cells. However, luteal cells from diabetic rats showed some loss of sensitivity in the synthesis of progesterone during incubation with hCG. Most of the alterations seen in diabetic female rats could be restored with insulin therapy, indicating that insulin plays an important role in the regulation and maintenance of normal reproductive functions. It is suggested that the diminution of the LH receptor population causes the disruption of normal luteal cell function. This fact could be responsible for some of the reproductive alterations in the diabetic female rat.

The effect of insulin (Ins) on luteal cell function was assayed and Ins binding was characterized in isolated collagenase-dispersed rat luteal cells. Ins stimulated progesterone production at concentrations over 10(-8) M, whereas human CG (hCG) produced maximal stimulation at 10(-11) M. Ins had an additive effect when it was added to the luteal cells in the presence of hCG in concentrations that produced submaximal stimulation. At 10(-9) M Ins the additive effect on hCG response became apparent (80% of maximal progesterone production). The maximal hCG response cannot be exceeded, even in the presence of high amounts of both hormones. hCG maximally stimulated cAMP production at 10(-10) M, whereas Ins neither stimulated cAMP production nor enhanced hCG response. Ins binding to luteal cells attained highest values after 30 min of incubation at 20 C. A curvilinear Scatchard plot was obtained and it was analyzed using a two-binding site model. The affinity constant values were 2.1 X 10(8) M-1 and 5.2 X 10(6) M-1 and the number of binding sites were 35,000 and 900,000 per cell, respectively. Bound Ins was not displaceable by hCG, human GH, human LH, epidermal growth factor, or ovine PRL. A protein moiety was essential for the receptor activity, since after trypsin digestion marked loss of binding was verified. Subcellular fractionation was performed and the highest binding was observed in the 105,000 X g pellet fraction. This study demonstrates that Ins binds specifically to rat luteal cells and stimulates steroidogenesis, adding support for the hypothesis that insulin acts directly upon the ovary.

The effect of streptozotocin-induced diabetes on circulating levels of immunoactive LH (I-LH) and bioactive LH (B-LH) was investigated. LH was measured in adult ovariectomized (OVX) rats before and after acute LHRH administration, with or without estradiol benzoate (Eb) treatment (10 micrograms, 48 and 24 h before experiments). I-LH and B-LH were measured in the same samples by RIA and the rat interstitial cell testosterone assay, respectively. OVX diabetic animals showed a significant reduction in both I-LH (63%) and B-LH (73%). Treatment with Eb induced a decrease in basal I-LH and B-LH levels in all experimental groups (50%). These values were normalized after insulin therapy. No alterations in the pituitary responsiveness to LHRH were detected when I-LH levels were determined. However, B-LH levels assayed after LHRH stimulation were significantly decreased in diabetic animals. Insulin treatment was unable to restore this response. The effect of Eb treatment on these parameters was also tested. In these conditions LHRH injections induced similar increases in serum I-LH and B-LH in both diabetic and control rats. These results indicate that, in diabetic OVX rats, basal and LHRH-induced LH has a reduced bioactivity, but this reduction is reversed by Eb treatment. This might indicate that the major defect lies in the ovary rather than at the pituitary level, supporting the notion of an important role of the steroid milieu on the B-LH modulation.